Circulation Research. 2003;92:518-524
Published online before print February 6, 2003, doi: 10.1161/01.RES.0000060700.55247.7C
Published online before print February 6, 2003, doi: 10.1161/01.RES.0000060700.55247.7C
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Molecular Medicine |
Peroxisome Proliferator-Activated Receptor (PPAR) 
and PPARß/
, but not PPAR
, Modulate the Expression of Genes Involved in Cardiac Lipid Metabolism
From the Department of Physiology (A.J.G., K.A.J.v.d.L., P.H.M.W., G.J.v.d.V., M.v.B.), Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands; U 545 INSERM, Département d’Athérosclerose (G.C., B.S.), Institut Pasteur de Lille and Faculté de Pharmacie, Université de Lille, France; and Department of Pediatrics (F.R.v.d.L.), Beatrix Children’s Hospital, University of Groningen, the Netherlands.
Correspondence to Dr M. van Bilsen, Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands. E-mail Marc.vanBilsen{at}FYS.Unimaas.NL
Long-chain fatty acids (FA) coordinately induce the expression of a panel of genes involved in cellular FA metabolism in cardiac muscle cells, thereby promoting their own metabolism. These effects are likely to be mediated by peroxisome proliferator-activated receptors (PPARs). Whereas the significance of PPAR
in FA-mediated expression has been demonstrated, the role of the PPARß/
and PPAR
isoforms in cardiac lipid metabolism is unknown. To explore the involvement of each of the PPAR isoforms, neonatal rat cardiomyocytes were exposed to FA or to ligands specific for either PPAR (Wy-14,643), PPARß/ (L-165041, GW501516), or PPAR (ciglitazone and rosiglitazone). Their effect on FA oxidation rate, expression of metabolic genes, and muscle-type carnitine palmitoyltransferase-1 (MCPT-1) promoter activity was determined. Consistent with the PPAR isoform expression pattern, the FA oxidation rate increased in cardiomyocytes exposed to PPAR and PPARß/ ligands, but not to PPAR ligands. Likewise, the FA-mediated expression of FA-handling proteins was mimicked by PPAR and PPARß/, but not by PPAR ligands. As expected, in embryonic rat heart-derived H9c2 cells, which only express PPARß/, the FA-induced expression of genes was mimicked by the PPARß/ ligand only, indicating that FA also act as ligands for the PPARß/ isoform. In cardiomyocytes, MCPT-1 promoter activity was unresponsive to PPAR ligands. However, addition of PPAR and PPARß/ ligands dose-dependently induced promoter activity. Collectively, the present findings demonstrate that, next to PPAR, PPARß/, but not PPAR, plays a prominent role in the regulation of cardiac lipid metabolism, thereby warranting further research into the role of PPARß/ in cardiac disease.
Key Words: cardiomyocytes • H9c2 cells • fatty acids • gene expression • uncoupling protein
This article has been cited by other articles:
 |
|
 |
|
  I. Torre-Villalvazo, F. Gonzalez, C. A. Aguilar-Salinas, A. R. Tovar, and N. Torres Dietary Soy Protein Reduces Cardiac Lipid Accumulation and the Ceramide Concentration in High-Fat Diet-Fed Rats and ob/ob Mice J. Nutr., December 1, 2009; 139(12): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ehrenborg and A. Krook Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor {delta} Pharmacol. Rev., September 1, 2009; 61(3): 373 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Hafstad, A. M. Khalid, M. Hagve, T. Lund, T. S. Larsen, D. L. Severson, K. Clarke, R. K. Berge, and E. Aasum Cardiac peroxisome proliferator-activated receptor-{alpha} activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss Cardiovasc Res, August 1, 2009; 83(3): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. H. Smeets, B. E. J. Teunissen, A. Planavila, H. de Vogel-van den Bosch, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPAR{alpha} and PPAR{delta} J. Biol. Chem., October 24, 2008; 283(43): 29109 - 29118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Faiola, J. G. Falls, R. A. Peterson, N. R. Bordelon, T. A. Brodie, C. A. Cummings, E. H. Romach, and R. T. Miller PPAR alpha, more than PPAR delta, Mediates the Hepatic and Skeletal Muscle Alterations Induced by the PPAR Agonist GW0742 Toxicol. Sci., October 1, 2008; 105(2): 384 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Witteles and M. B. Fowler Reply. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Chess and W. C. Stanley Role of diet and fuel overabundance in the development and progression of heart failure Cardiovasc Res, July 15, 2008; 79(2): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ventura-Clapier, A. Garnier, and V. Veksler Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha} Cardiovasc Res, July 15, 2008; 79(2): 208 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-L. Yue, S. S. Nerurkar, W. Bao, B. M. Jucker, L. Sarov-Blat, K. Steplewski, E. H. Ohlstein, and R. N. Willette In Vivo Activation of Peroxisome Proliferator-Activated Receptor-{delta} Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gelinas, F. Labarthe, B. Bouchard, J. Mc Duff, G. Charron, M. E. Young, and C. Des Rosiers Alterations in carbohydrate metabolism and its regulation in PPAR{alpha} null mouse hearts Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1571 - H1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Montessuit, I. Papageorgiou, and R. Lerch Nuclear Receptor Agonists Improve Insulin Responsiveness in Cultured Cardiomyocytes through Enhanced Signaling and Preserved Cytoskeletal Architecture Endocrinology, March 1, 2008; 149(3): 1064 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez-Calvo, L. Serrano, E. Barroso, T. Coll, X. Palomer, A. Camins, R. M. Sanchez, M. Alegret, M. Merlos, M. Pallas, et al. Peroxisome Proliferator-Activated Receptor {alpha} Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2007; 62(12): 1326 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Schaiff, F. F. Knapp Jr., Y. Barak, T. Biron-Shental, D. M. Nelson, and Y. Sadovsky Ligand-Activated Peroxisome Proliferator Activated Receptor {gamma} Alters Placental Morphology and Placental Fatty Acid Uptake in Mice Endocrinology, August 1, 2007; 148(8): 3625 - 3634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E.J. Teunissen, P. J.H. Smeets, P. H.M. Willemsen, L. J. De Windt, G. J. Van der Vusse, and M. Van Bilsen Activation of PPAR{delta} inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts Cardiovasc Res, August 1, 2007; 75(3): 519 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Finck and D. P. Kelly Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease Circulation, May 15, 2007; 115(19): 2540 - 2548. [Full Text] [PDF]
|
|
|
|
 |
|
 T.-A. S. Duhaney, L. Cui, M. K. Rude, N. K. Lebrasseur, S. Ngoy, D. S. De Silva, D. A. Siwik, R. Liao, and F. Sam Peroxisome Proliferator-Activated Receptor {alpha}-Independent Actions of Fenofibrate Exacerbates Left Ventricular Dilation and Fibrosis in Chronic Pressure Overload Hypertension, May 1, 2007; 49(5): 1084 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy Cardiovasc Res, January 15, 2007; 73(2): 257 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Finck The PPAR regulatory system in cardiac physiology and disease Cardiovasc Res, January 15, 2007; 73(2): 269 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. An and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Smith and G. E. O. Muscat Orphan nuclear receptors: therapeutic opportunities in skeletal muscle Am J Physiol Cell Physiol, August 1, 2006; 291(2): C203 - C217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Murray, C. A. Lygate, M. A. Cole, C. A. Carr, G. K. Radda, S. Neubauer, and K. Clarke Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart Cardiovasc Res, July 1, 2006; 71(1): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Benton, D. P. Y. Koonen, J. Calles-Escandon, N. N. Tandon, J. F. C. Glatz, J. J. F. P. Luiken, J. J. Heikkila, and A. Bonen Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle J. Physiol., May 15, 2006; 573(1): 199 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Morgan, J. H. Rennison, M. E. Young, T. A. McElfresh, T. A. Kung, K.-Y. Tserng, B. D. Hoit, W. C. Stanley, and M. P. Chandler Effects of chronic activation of peroxisome proliferator-activated receptor-{alpha} or high-fat feeding in a rat infarct model of heart failure Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1899 - H1904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Verreth, J. Ganame, A. Mertens, H. Bernar, M.-C. Herregods, and P. Holvoet Peroxisome Proliferator-Activated Receptor-{alpha},{gamma}-Agonist Improves Insulin Sensitivity and Prevents Loss of Left Ventricular Function in Obese Dyslipidemic Mice Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 922 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pesant, S. Sueur, P. Dutartre, M. Tallandier, P. A. Grimaldi, L. Rochette, and J.-L. Connat Peroxisome proliferator-activated receptor {delta} (PPAR{delta}) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovasc Res, February 1, 2006; 69(2): 440 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Benkirane, F. Amiri, Q. N. Diep, M. El Mabrouk, and E. L. Schiffrin PPAR-{gamma} inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1 Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H390 - H397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Murray, M. Panagia, D. Hauton, G. F. Gibbons, and K. Clarke Plasma Free Fatty Acids and Peroxisome Proliferator-Activated Receptor {alpha} in the Control of Myocardial Uncoupling Protein Levels Diabetes, December 1, 2005; 54(12): 3496 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention PNAS, June 28, 2005; 102(26): 9406 - 9411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. M. Coort, W. A. Coumans, A. Bonen, G. J. van der Vusse, J. F. C. Glatz, and J. J. F. P. Luiken Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats J. Lipid Res., June 1, 2005; 46(6): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Planavila, J. C. Laguna, and M. Vazquez-Carrera Nuclear Factor-{kappa}B Activation Leads to Down-regulation of Fatty Acid Oxidation during Cardiac Hypertrophy J. Biol. Chem., April 29, 2005; 280(17): 17464 - 17471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Kramer, L. Al-Khalili, S. Perrini, J. Skogsberg, P. Wretenberg, K. Kannisto, H. Wallberg-Henriksson, E. Ehrenborg, J. R. Zierath, and A. Krook Direct Activation of Glucose Transport in Primary Human Myotubes After Activation of Peroxisome Proliferator-Activated Receptor {delta} Diabetes, April 1, 2005; 54(4): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Petrashevskaya and A. Schwarz Peroxisome proliferator-activated receptor {beta}/{delta}: a new antihypertrophic drug target? Cardiovasc Res, March 1, 2005; 65(4): 770 - 771. [Full Text] [PDF]
|
|
|
|
|
|
A. Planavila, R. Rodriguez-Calvo, M. Jove, L. Michalik, W. Wahli, J. C. Laguna, and M. Vazquez-Carrera Peroxisome proliferator-activated receptor {beta}/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes Cardiovasc Res, March 1, 2005; 65(4): 832 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin Peroxisome proliferator-activated receptors and cardiovascular remodeling Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1037 - H1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Lavrentyev, D. He, and G. A. Cook Expression of genes participating in regulation of fatty acid and glucose utilization and energy metabolism in developing rat hearts Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2035 - H2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Huss and D. P. Kelly Nuclear Receptor Signaling and Cardiac Energetics Circ. Res., September 17, 2004; 95(6): 568 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bartelds, J. Takens, G. B. Smid, V. A. Zammit, C. Prip-Buus, J. R. G. Kuipers, and F. R. van der Leij Myocardial carnitine palmitoyltransferase I expression and long-chain fatty acid oxidation in fetal and newborn lambs Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2243 - H2248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Carley, L. M. Semeniuk, Y. Shimoni, E. Aasum, T. S. Larsen, J. P. Berger, and D. L. Severson Treatment of type 2 diabetic db/db mice with a novel PPAR{gamma} agonist improves cardiac metabolism but not contractile function Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E449 - E455. [Abstract] [Full Text]
|
|
|
|
|
|
K. Feingold, M. S. Kim, J. Shigenaga, A. Moser, and C. Grunfeld Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E201 - E207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, P. J.H Smeets, A. J Gilde, and G. J van der Vusse Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res, February 1, 2004; 61(2): 218 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Dressel, T. L. Allen, J. B. Pippal, P. R. Rohde, P. Lau, and G. E. O. Muscat The Peroxisome Proliferator-Activated Receptor {beta}/{delta} Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells Mol. Endocrinol., December 1, 2003; 17(12): 2477 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Russell, J. Feilchenfeldt, S. Schreiber, M. Praz, A. Crettenand, C. Gobelet, C. A. Meier, D. R. Bell, A. Kralli, J.-P. Giacobino, et al. Endurance Training in Humans Leads to Fiber Type-Specific Increases in Levels of Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator-1 and Peroxisome Proliferator-Activated Receptor-{alpha} in Skeletal Muscle Diabetes, December 1, 2003; 52(12): 2874 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iglarz, R. M. Touyz, E. C. Viel, P. Paradis, F. Amiri, Q. N. Diep, and E. L. Schiffrin Peroxisome Proliferator-Activated Receptor-{alpha} and Receptor-{gamma} Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension Hypertension, October 1, 2003; 42(4): 737 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin, F. Amiri, K. Benkirane, M. Iglarz, and Q. N. Diep Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension Hypertension, October 1, 2003; 42(4): 664 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Kelly PPARs of the Heart: Three Is a Crowd Circ. Res., March 21, 2003; 92(5): 482 - 484. [Full Text] [PDF]
|
|